Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 8/20 | 0.52 |
| ▸ | HTR1B | P28222 | 8/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HTR1F | P30939 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775993 | 0.80 | CACNA1C (0.50) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL3647546 | 0.76 | CACNA1C (0.50) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL29158180 | 0.76 | HTR1D (0.46) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL825618 | 0.76 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL15304333 | 0.76 | HTR1D (0.48) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL5311822 | 0.76 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL15947200 | 0.76 | HTR1D (0.48) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL3647544 | 0.76 | CACNA1C (0.50) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL531572 | 0.76 | HTR1D (0.48) | HTR1DHTR1BHTR1AHTR2AKMT2A | |
| SCHEMBL29158176 | 0.76 | HTR1D (0.46) | HTR1DHTR1BHTR1AHTR2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| EP-1411942-A4 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1411942-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | Synaptic Pharmaceutical Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| EP-1246847-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002002744-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-01-10 | — | — | WO | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | HTR1D 46/4885HTR1B 65/4885HTR1A 34/4885 |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | HTR1D 24/4885HTR1B 35/4885HTR1A 29/4885 |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | HTR1D 105/4885HTR1B 234/4885HTR1A 86/4885 |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | HTR1D 46/4885HTR1B 65/4885HTR1A 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.